Neuralstem

 

Posted on Tuesday, January 13, 2015 - 12:04, By: Margaret Wahl
Update (March 17, 2015): Neuralstem announced on March 12, 2015, that a phase 2 trial to test transplantation into the spinal cord of its NSI-566 neural stem cells showed the procedure was generally safe and well tolerated in 15 ALS patients (with one exception) and that stabilization or...

Five short items about the state of ALS science addressing: a therapy targeting SOD1; roles for TDP43 in behavior and body fat; respiratory care; and more

Posted on Tuesday, September 24, 2013 - 14:45, By: Amy Madsen
This roundup of recent amyotrophic lateral sclerosis (ALS) research and clinical trials news includes:

Six short items about the state of ALS science: Neuralstem and Cytokinetics ALS clinical trials; weight maintenance in ALS; stem cell technology; and more

Posted on Thursday, September 12, 2013 - 05:00, By: Amy Madsen
This roundup of recent amyotrophic lateral sclerosis (ALS) research and clinical trials news includes:

Neuralstem reports that participants with limb-onset ALS who were early in their disease course had better outcomes in its trial

Posted on Wednesday, May 22, 2013 - 01:27, By: Amy Madsen
Recently announced data from a phase 1 clinical trial of NSI-566 neural stem cells in people with amyotrophic lateral sclerosis (ALS) show that a subset of trial participants had better outcomes than the others.

Neuralstem will conduct a phase 2 dose-escalation and safety trial to test its ‘NSI-566’ neural stem cells in people with amyotrophic lateral sclerosis

Posted on Wednesday, April 17, 2013 - 12:31, By: Amy Madsen
Maryland biotherapeutics company Neuralstem today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to conduct a phase 2 clinical trial to test its NSI-566 neural stem cells in people with amyotrophic lateral sclerosis (ALS).

Updates on several important clinical trials were presented at an international ALS conference in December, including reports on ISIS-SOD1-Rx, NP001, neural stem cells, olesoxime and tirasemtiv

Posted on Thursday, December 13, 2012 - 16:11, By: Amy Madsen
The 23rd International Symposium on ALS/MND (motor neuron disease), held in Chicago Dec. 5-7, 2012, brought together more than 900 researchers, clinicians and other health care professionals from 30 countries to hear presentations on the latest in ALS care and research.

Neuralstem is seeking permission to evaluate efficacy in its phase 1 safety trial, as well as to increase the dosage and number of trial participants

Posted on Wednesday, May 16, 2012 - 04:39, By: Amy Madsen
The biotherapeutics company Neuralstem is seeking to amend the design of its ongoing phase 1 stem cell trial in amyotrophic lateral sclerosis (ALS) to include evaluations of efficacy (how well the therapy works). Although the phase 1 trial isn’t currently designed to evaluate efficacy, early...

Advertisements

myMuscleTeam